Mebeverine For Daytime And Nocturnal Incontinence and After Orthotopic W-Ileal Neobladders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03147599|
Recruitment Status : Unknown
Verified May 2017 by Abdelwahab Hashem, Mansoura University.
Recruitment status was: Recruiting
First Posted : May 10, 2017
Last Update Posted : May 17, 2017
|Condition or disease||Intervention/treatment||Phase|
|Oncology Incontinence Incontinence, Daytime Urinary Incontinence, Nighttime Urinary Bladder Cancer Orthotopic Neobladder||Drug: Coloverin Drug: Placebo||Phase 4|
In appropriately selected patients an orthotopic neobladder (ONB) permits the elimination of an external stoma and preservation of body image without compromising cancer control after radical cystectomy. Voiding dysfunction (VD) following ONB can be divided into failure to empty bladder or failure to store urine. Failure to empty bladder by angulation of urethra is the most common cause. Failure to store urine can occur during daytime, night-time or both. VD that persists beyond 6 to 12 months warrants urodynamics evaluation to determine the cause and suggest plane of therapy. Voiding dysfunction has a detrimental impact on quality of life.
Among the various bowel segments studied, the ileum is ideal for ONB creation. A spherical reservoir, reconfigured from a de-tubularized ileal segment, offers the most desirable attributes like, adequate capacity, low intraluminal pressure, and good compliance. The patient of ONB reported 4-25% rate of clean intermittent self-catheterisation (CISC) for incomplete emptying. Daytime incontinence was present in 13% of patients. The rate of nocturnal incontinence is usually higher in the range of 15-40% in recent metanalysis. The success of ONB rely on detubularization of intestinal segment, sufficient capacity and proper configuration and position in the pelvis. Adequate capacity is achieved by using sufficient length, folding, and creation an ellipsoid or spherical configuration. The ONB should hold approximately 500 cc of urine at low pressure (at < 15 cm H2O), empty completely (< 100 cc urine), four to five times daily and allow the patient to sleep without awakening, while maintain normal body image
loss of the vesico-urethral reflex 'guarding reflex' in which increased urethral sphincter tone parallel to bladder distension, decreased patient vigilance during sleep resulting in reduced muscle tone and urethral closing pressure, decreased sensitivity of the membranous urethra after radical cystectomy, involuntary high-amplitude contractions of the reservoir secondary to bowel peristalsis and shifting of free water from the reservoir wall into the hyperosmolar urine are the main factor causing global and nocturnal polyuria in patient with ONB. Final, there is also evidence suggesting an increase in bowel activity during sleep. Maximum urethral closing pressure (MUCP) is the primary component responsible for daytime continence in patients with an ONB. However, Koraitim et al. suggest that nocturnal incontinence depends on three reservoir parameters: maximal contraction amplitude, baseline reservoir pressure at mid capacity, and MUCP.
Mebeverine is a derivative of reserpine, which has relatively specific effects on smooth muscle cells without atropine-like side effects in humans. It directly blocks voltage-operated sodium channels and inhibits intracellular calcium accumulation. It is three times more potent than papaverine in inhibiting the peristaltic reflex of the ileum.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Mebeverine For Daytime And Nocturnal Incontinence and After Orthotopic W-Ileal Neobladders - Assessment Of Efficacy And Quality Of Life Effect Within 1 Year Post-Surgery: A Randomized Cross-over Controlled Study|
|Estimated Study Start Date :||May 15, 2017|
|Estimated Primary Completion Date :||December 1, 2017|
|Estimated Study Completion Date :||December 1, 2017|
Active Comparator: Mebeverine
Coloverin (Mebeverine hydrochloride 135 mg)
Mebeverine hydrochloride 135 mg
Other Name: Mebeverine hydrochloride
Placebo Comparator: Placebo
- Effect of mebeverine on daytime and nocturnal incontinence by assessing continence status measured by standardized continence questionnaire [ Time Frame: 10 months ]Outcome Measure by standardized continence questionnaire
- Effect of mebeverine on patient quality of life by assessing patient quality of life measured by quality of life questionnaire [ Time Frame: 10 months ]Outcome Measure by quality of life questionnaire
- Effect of mebeverine on orthotopic w-ileal neobladders urodynamics by assessing simple urodynamic parameter [ Time Frame: 10 months ]Outcome Measure by pressure change measurement in centimetre of water.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03147599
|Contact: Abdelwahab R. Hashem, Msc||01069678979 ext email@example.com|
|Contact: Mohammed H. Zahran, MD||01063338690 ext firstname.lastname@example.org|
|Study Chair:||Hassan Abol-Enein, MD||Urology and Nephrology Center|
|Study Director:||Ahmed Mosbah, MD||Urology and Nephrology Center|
|Principal Investigator:||Ahmed Elhussein, MBBCH||Urology and Nephrology Center|
|Principal Investigator:||Ahmed Elkarta, MBBCH||Urology and Nephrology Center|
|Principal Investigator:||Mohamed Soltan, MBBCH||Urology and Nephrology Center|